{"disease":{"id":"covid-19-induced-pneumonia","name":"covid 19 induced pneumonia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04362813","title":"Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":454,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04535674","title":"Asunercept in Patients With Severe COVID-19","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":438,"lead_sponsor_name":"Apogenix AG","has_results":false},{"nct_id":"NCT04476706","title":"Canakinumab MAP in COVID-19 Pneumonia With CRS","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}